These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28039264)

  • 1. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
    Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
    Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
    [No Abstract]   [Full Text] [Related]  

  • 2. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
    Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.
    Li S; Wei Q; Li Q; Zhang B; Xiao Q
    Cancer Biol Ther; 2015; 16(6):866-75. PubMed ID: 25920936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
    Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
    Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
    Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
    PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.
    Tanaka T; Ikegami Y; Nakazawa H; Kuriyama N; Oki M; Hanai J; Sukhatme VP; Kaneki M
    J Cell Physiol; 2017 Jan; 232(1):192-201. PubMed ID: 27137755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
    Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
    Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.
    Liao D; Corle C; Seagroves TN; Johnson RS
    Cancer Res; 2007 Jan; 67(2):563-72. PubMed ID: 17234764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
    Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
    Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.
    Moschetta MG; Maschio LB; Jardim-Perassi BV; Gelaleti GB; Lopes JR; Leonel C; Gonçalves Ndo N; Ferreira LC; Martins GR; Borin TF; Zuccari DA
    Oncol Rep; 2015 May; 33(5):2345-53. PubMed ID: 25779537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model.
    Kim DH; Sung B; Kim JA; Kang YJ; Hwang SY; Hwang NL; Suh H; Choi YH; Im E; Chung HY; Kim ND
    Int J Oncol; 2017 Aug; 51(2):715-723. PubMed ID: 28656256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
    Park JM; Terabe M; Sakai Y; Munasinghe J; Forni G; Morris JC; Berzofsky JA
    J Immunol; 2005 Apr; 174(7):4228-36. PubMed ID: 15778385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
    Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
    Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA LINC00649 promotes the growth and metastasis of triple-negative breast cancer by maintaining the stability of HIF-1α through the NF90/NF45 complex.
    Zhang J; Du C; Zhang L; Wang Y; Zhang Y; Li J
    Cell Cycle; 2022 May; 21(10):1034-1047. PubMed ID: 35188449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
    Mahdevar E; Kefayat A; Safavi A; Behnia A; Hejazi SH; Javid A; Ghahremani F
    Sci Rep; 2021 Nov; 11(1):23121. PubMed ID: 34848739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance.
    Whelan KA; Schwab LP; Karakashev SV; Franchetti L; Johannes GJ; Seagroves TN; Reginato MJ
    J Biol Chem; 2013 May; 288(22):15865-77. PubMed ID: 23585570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.